Last edition
News about "metastatic breast cancer "
Evexta Bio, Roche Partner to Evaluate Novel Breast Cancer Combination Therapy
Evexta Bio has entered a clinical collaboration with Roche to evaluate its investigational therapy rupitasertib in combination with giredestrant for the treatment of advanced ER+, HER2-, ESR1-mutated breast cancer.
Metastatic Breast Cancer | 05/08/2026 | By News Bureau
Evexta Bio, Roche Partner to Evaluate Novel Breast Cancer Combination Therapy
Evexta Bio has entered a clinical collaboration with Roche to evaluate its investigational therapy rupitasertib in combination with giredestrant for the treatment of advanced ER+, HER2-, ESR1-mutated breast cancer.
Metastatic Breast Cancer | 05/08/2026 | By News Bureau
EU Approves AstraZeneca's Etcamah Combination for ESR1-Mutated Advanced Breast Cancer
The European Commission has approved AstraZeneca’s Etcamah in combination with CDK4/6 inhibitors for ESR1-mutated ER-positive, HER2-negative advanced breast cancer, following Phase 3 data demonstrating a 56% reduction in the risk of disease progression or death.
Metastatic Breast Cancer | 24/07/2026 | By News Bureau
US FDA Approves Pfizer's Ibrance for Maintenance Treatment of HR+, HER2+ Metastatic Breast Cancer
FDA approval makes Ibrance the first CDK4/6 inhibitor indicated for HR+ metastatic breast cancer regardless of HER2 status.
Metastatic Breast Cancer | 26/06/2026 | By News Bureau | 254
The European Commission has approved Trodelvy for first-line treatment of unresectable or metastatic triple-negative breast cancer, offering a new therapeutic option for patients with one of the most aggressive forms of breast cancer.
Metastatic Breast Cancer | 25/06/2026 | By News Bureau
Lupin and Natco Secure USFDA Approval for Generic Cancer Drug Eribulin Mesylate Injection
Lupin and Natco Pharma have received USFDA approval for Eribulin Mesylate Injection, a generic equivalent of Halaven, used in the treatment of advanced breast cancer and liposarcoma.
Metastatic Breast Cancer | 03/06/2026 | By News Bureau
Biotheryx Doses First Patient in Dose Expansion Trial of BTX-9341 for Advanced Breast Cancer
Biotheryx advances BTX-9341 into a dose expansion trial with fulvestrant for HR+/HER2- breast cancer, aiming to overcome resistance in patients previously treated with CDK4/6 inhibitors.
Metastatic Breast Cancer | 19/03/2026 | By News Bureau | 163
The UK regulator has approved Inluriyo (imlunestrant tosylate) for adults with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations after prior hormone therapy failure.
Metastatic Breast Cancer | 26/02/2026 | By News Bureau | 200
Daiichi Sankyo Files sNDA in Japan for ENHERTU Plus Pertuzumab in HER2-Positive Breast Cancer
Daiichi Sankyo has filed a supplemental NDA in Japan for ENHERTU plus Pertuzumab in HER2-positive breast cancer. If approved, this therapy could enter the first-line metastatic setting and has the potential to become a new standard of care.
<br />
Metastatic Breast Cancer | 08/10/2025 | By Dineshwori | 564
Roche Reports Positive Results from Phase III evERA Breast Cancer Study
Roche has announced positive results from the phase III evERA study evaluating its investigational oral selective oestrogen receptor degrader (SERD), giredestrant, in combination with everolimus in people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer.
Metastatic Breast Cancer | 24/09/2025 | By Dineshwori | 195
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy